Search for Clinical Trial Results
Carcinoma, Papillary - 33 Studies Found
Status | Study |
Terminated |
Study Name: Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Condition:
|
Withdrawn |
Study Name: Research Study in Patients With Advanced Ovarian Epithelial Cancer Condition:
|
Not yet recruiting |
Study Name: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Condition:
|
Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition:
|
Active, not recruiting |
Study Name: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Condition:
|
Recruiting |
Study Name: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition:
|
Active, not recruiting |
Study Name: Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Condition:
|
Active, not recruiting |
Study Name: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Condition:
|
Not yet recruiting |
Study Name: Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Condition:
|
Recruiting |
Study Name: Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Condition: Thyroid Papillary Carcinoma Date: 2015-12-13 Interventions:
|